DIPEPTIDYL PEPTIDASE-IV (DPP-IV) INHIBITORY ACTIVITY OF METFORMIN

Allenki Venkatesham, Devarakonda Krishna, Yellu Reddy, Yellu Reddy, M Pharm
2008 Pharmacologyonline   unpublished
Dipeptidyl peptidase IV is plasma membrane glycoprotein exopeptidase, inhibition of DPP-IV activity could be a useful strategy to enhance the activity of GLP-1. GLP-1 is an incretin released from L cells in the intestine after oral ingestion of nutrients. GLP-1 (7-37) is actively being evaluated as a therapy for diabetes mellitus. Metformin is an oral biguanide agent used for the treatment of type 2 diabetes. Male Wistar rats were used for the study. Serum glucose and DPP-IV levels (0 day) were
more » ... compared with post treatment values on day 15 th. Lipid profiles were determined after 15 th day drug treatment. In alloxan induced diabetic rats, acute administration of metformin significantly reduced the serum glucose and DPP-IV levels from 0 day to until the end of the experiment. Similarly there was a significance influence on lipid profile on acute administration of metformin drug treated in alloxan induced diabetic rats. DPP-IV levels and lipid profiles were reduced (except HDL) in metformin drug treated diabetic rats. Therefore, metformin used a DPP-IV inhibitor and anti-dyslipidimic effect. The present investigation thus encourages the development of new metformin analogues with better DPP-IV activity.
fatcat:crgkqcg4i5dtnjgap5vzcaixqa